No abstract was published with this document — society guidelines, consensus pathways, and scientific statements are typically released without one. See the Key Points and the linked PDF for the full content.
“The timing of invasive therapy in medium- and high-risk patients. The role of triple- vs. dual-antiplatelet therapy in patients at medium and high risk. The role of invasive therapy in patients with chronic kidney disease. The importance of participating in quality improvement processes. The role of prasugrel in non–ST elevation acute coronary syndrome.”
Wright et al. (2011) studied this question.